Suresh Jadhav

Executive Director
Serum Institute India (SII)

Dr.Suresh Jadhav, M.Pharm., Ph.D. is the Executive Director of Serum Institute of India Pvt. Ltd. His 47 years technical expertise includes QC/QA/cGMP/GLP/GCP techniques, inspections of laboratories and validation of various production and quality control processes, pharma/toxicological screening of various drugs, toxins & venoms etc. & drugs pricing. He successfully led the project of development and introduction of Meningococcal A Conjugate Vaccine in Sub-Saharan African belt, the development of Seasonal & Pandemic Influenza Vaccines and also played major role in acquisition of Bilthoven Biologicals, The Netherlands. He is also actively involved in the development of vaccines against Covid-19 infection. Being associated with DCVMN since its inception, Dr.Jadhav was its President for 5 years. He held the positions of GAVI Board / Alternate member as also member of GAVI PPC. He is also member on European Vaccine Initiative, FastVac, and Health Innovation in Practice Board etc. He is closely associated with various advisory committees e.g. Task Force of Sabin Vaccine Institute, WHO IVR-IVAC and Decades of Vaccines (DoV) etc. Dr.Jadhav is also affiliated with several Indian universities, AICTE, UGC, State Directorate of Technical Education etc. He is the Chairman of Expert Committee on Vaccines and other Biologicals and also a member on the Scientific Body of Indian Pharmacopoeia Commission. He has participated in several collaborative studies for making revisions in international reference standards for WHO, NIBSC, NVI/RIVM etc. and has published more than 100 technical papers in national & international journals, with extensive travel throughout the globe. He has to his credit two patents in his name. Ranked at 7th position amongst World’s 50 most influential people in Vaccines surveyed by Vaccinenation of Terrapinn. He is conferred with IPA Pune Lifetime Achievement Award 2015 by Indian Pharmaceutical Association.